Polaino v. Bayer Corp.

122 F. Supp. 2d 63, 2000 U.S. Dist. LEXIS 19278, 2000 WL 1737856
CourtDistrict Court, D. Massachusetts
DecidedNovember 13, 2000
Docket1:97-cv-11420
StatusPublished
Cited by8 cases

This text of 122 F. Supp. 2d 63 (Polaino v. Bayer Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Polaino v. Bayer Corp., 122 F. Supp. 2d 63, 2000 U.S. Dist. LEXIS 19278, 2000 WL 1737856 (D. Mass. 2000).

Opinion

MEMORANDUM AND ORDER ON DEFENDANTS’ MOTIONS TO STRIKE AND MOTIONS FOR ' SUMMARY JUDGMENT

STEARNS, District Judge.

On June 23, 1997, Alfred Polaino, an x-ray technician at the New Bedford Veteran’s Administration Hospital (VA), brought this Complaint against the AGFA division of Bayer Corporation (AGFA), X.R. Imaging Network, Inc. (XRI), and White Mountain Imaging (White Mountain). Polaino alleges that he contracted an acute respiratory illness from chemical fumes emitted by an x-ray film processor and mixer manufactured and distributed by the defendants.

The Second Amended Complaint is framed on claims of a breach of the implied warranty of merchantability, negligence, and loss of consortium. 1 The Complaint alleges, in somewhat indiscriminate fashion, that the defendants collectively “sold and [negligently] installed the film processor and chemical mixer” without a device to warn “that there was no water in the mixture as required.”

PROCEDURAL HISTORY

On June 9, 1999, the defendants filed motions for summary judgment. 2 The undisputed facts insofar as relevant to these motions are as follows. In the fall of 1996, the VA purchased a Curix Compact Plus x-ray processor from AGFA. The AGFA processor permitted a technician to load x- *65 ray cassettes without touching the film. The VA also acquired an IS-199 White Mountain chemical mixer from XRI. The White Mountain mixer automatically dilutes the processing chemicals with water and delivers a calibrated solution to the processor. The mixer is, however, a nonessential component. A technician has the ability to manually add the proper mix of water and chemicals directly to the processor.

In November of 1996, a VA employee and an AGFA representative installed the processor. During the installation, employees from XRI arrived with the mixer. It is not clear who installed the mixer. On December 13, 1996, Polaino began using the new equipment, processing six to eight x-ray exposures daily. On December 24, 1996, Polaino experienced sleeplessness and shortness of breath. His condition worsened, causing him to miss work. His treating physician (Dr. Bundy) determined that he was suffering from interstitial pneumonitis. Polaino returned to work on January 7, 1997. On January 21, 1997, an XRI service representative discovered that the water line to the mixer had been shut off. (He also discovered that an overflow line had never been installed). As a result, undiluted chemicals were being delivered from the mixer to the processor. Polaino believes that fumes from these undiluted chemicals caused his respiratory illness.

On November 4, 1999, the court heard oral argument on the defendants’ motions. On December 10, 1999, the court allowed the motions in part, holding: (1) that Po-laino had waived any duty to warn claim; (2) that the design defect claim was untenable against AGFA, which had no role in the 'design, manufacture, or distribution of the mixer; and (3) that Polaino’s negligent installation claim against White Mountain (“and so much of the breach of warranty claim that relies on a similar premise”) should be dismissed because White Mountain had played no role in installing the equipment. The court also found Polaino’s expert disclosures deficient, observing that:

[defendants’ main argument, however, is that Polaino has failed to identify an expert witness competent to testify to a design defect in the mixer or to establish a link between Polaino’s medical complaints and the mixer’s design or installation .... [Fn 8: I assume that Polaino intends to establish the feasibility of an alternate design by pointing to the AGFA processor which, in fact, is armed with a water alarm. Even if that were sufficient, Polaino would still need to establish that exposure to the undiluted chemicals used in the mixer, as opposed to the chemicals generally, caused his ailments.]
While the court would ordinarily find Polaino’s failure to comply with Rule 26 fatal, it is mindful of the fact that it has forgiven the defendants’ prior disregard of the court’s scheduling order in permitting them to file their summary judgment motions late. In fairness, Polaino should be given a similar second bite at the apple. The court will reopen the discovery schedule as follows. Polaino will have 46 days to designate appropriate experts on causation and to file a proper Rule 26 statement. Defendants will have 45 days thereafter to depose plaintiffs’ experts, if they choose. Summary judgment motions may be filed 30 days thereafter, limited, however, to the issues of design defect and causation.

Polaino thereafter designated two expert witnesses: Dr. Harvey M. Cohen and Dr. Robert J. Bundy. On April 17, 2000, AGFA filed a motion in limine to preclude the testimony of Dr. Cohen and Dr. Bun-dy. On April 19, 2000, White Mountain and XRI followed suit with a joint motion seeking to exclude Dr. Cohen’s testimony on different grounds. 3 The court heard *66 oral argument on the motions on September 28, 2000.

DISCUSSION

As pruned by the court’s prior rulings, the Second Amended Complaint alleges a design defect claim against White Mountain and XRI, as manufacturer and distributor, respectively, of the mixer, and negligence and breach of warranty claims against XRI and AGFA alleging improper installation of the mixer. White Mountain and XRI have moved, pursuant to Fed. R.Evid. 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), to exclude Dr. Cohen’s testimony to the extent that it is being offered in support of the design defect claim. AGFA also challenges Dr. Cohen’s opinions regarding general and specific causation.

Daubert, and two subsequent cases, General Electric Co. v. Joiner, 522 U.S. 136, 118 S.Ct. 512, 139 L.Ed.2d 508 (1997), and Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 119 S.Ct. 1167, 143 L.Ed.2d 238 (1999), have radically altered the approach of the federal trial court to expert testimony. In Daubert, the Supreme Court abandoned the general acceptance test of Frye v. United States, 293 F. 1013 (D.C.Cir.1923), finding it superseded by the more flexible relevancy test of Fed. R.Evid. 702. “That the Frye test was displaced by the Rules of Evidence does not mean, however, that the Rules themselves place no limits on the admissibility of purportedly scientific evidence.” Daubert, supra, at 589, 113 S.Ct. 2786. Daubert

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Walters v. Flint
E.D. Michigan, 2021
Carrozza v. CVS Pharmacy, Inc.
992 F.3d 44 (First Circuit, 2021)
Carrozza v. CVS Pharmacy, Inc.
D. Massachusetts, 2019
Carrozza v. CVS Pharmacy, Inc.
391 F. Supp. 3d 136 (District of Columbia, 2019)
Kerlinsky v. Sandoz, Inc.
783 F. Supp. 2d 236 (D. Massachusetts, 2011)
Allen v. Martin Surfacing
263 F.R.D. 47 (D. Massachusetts, 2009)
Coleman v. Dydula
139 F. Supp. 2d 388 (W.D. New York, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
122 F. Supp. 2d 63, 2000 U.S. Dist. LEXIS 19278, 2000 WL 1737856, Counsel Stack Legal Research, https://law.counselstack.com/opinion/polaino-v-bayer-corp-mad-2000.